acalabrutinib
astrazeneca
['leusm', 'acalabrutinib', 'cll']
acalabrutinib monotherapy maintains favorable efficacy over soc approaches in relapsed/refractory cll #eha22 #leusm 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.